• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在注射[镓]Ga-FAPI-04后34分钟,探索[氟]FDG/[镓]Ga-FAPI-04双低活度示踪剂一站式全身PET成像的可行性和附加价值。

Exploration the feasibility and additional value of [F]FDG/[Ga]Ga-FAPI-04 dual-low-activity-tracer one-stop total-body PET imaging at 34 min post-injection of [Ga]Ga-FAPI-04.

作者信息

Zheng Zhe, He Yibo, Mao Wujian, Yu Haojun, Wu Ha, Yang Runjun, Gao Huaping, Hu Pengcheng, Shi Hongcheng

机构信息

Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.

Shanghai Institute of Medical Imaging, Shanghai, 200032, China.

出版信息

Eur J Nucl Med Mol Imaging. 2025 Jan;52(2):638-647. doi: 10.1007/s00259-024-06924-2. Epub 2024 Sep 25.

DOI:10.1007/s00259-024-06924-2
PMID:39320482
Abstract

OBJECTIVES

To validate the feasibility of one-stop 2-[F]fluoro-2-deoxy-D-glucose ([F]FDG) and [Ga]Ga-fibroblast activation protein inhibitor-04 ([Ga]Ga-FAPI-04) dual-low-activity-tracer positron emission tomography/computed tomography (PET/CT) at 34 min post-injection of [Ga]Ga-FAPI-04 and explore its additional value.

METHODS

Thirty pairs of patients with suspected malignancies who underwent dual-tracer imaging were enrolled in this retrospective study. The images were reconstructed at 34-39 and 50-60 min after additional injection of [Ga]Ga-FAPI-04 (in one-stop FDG-FAPI PET/CT, named PET, PET, and PET; in the 2-day protocol, named PET, PET, and PET, respectively). Tumour-to-normal ratios (TNR) of lesions in PET, PET, and PET and TNR of lesions in PET and PET were evaluated separately. To evaluate the potential added value of one-stop FDG-FAPI PET/CT over the 2-day protocol, TNRs of PET, PET, and PET were compared with PET. The lesion detectability of the two imaging protocols was evaluated by chi-square test.

RESULTS

Comparing FAPI-weighted PET (PET and PET) and single-tracer imaging (PET) in one-stop FDG-FAPI PET/CT, TNRs of FAPI-weighted PET were higher than those of PET. PET and PET showed similar performance in lesion detectability and TNRs (all P > 0.05). In the 2-day protocol, there are no statistically significant differences in TNRs of all lesions at PET and PET. Comparing one-stop FDG-FAPI PET/CT with the 2-day protocol, TNRs of PET were significantly higher than those of PET but lower than those of PET and PET. Lesion detectability in the one-stop FDG-FAPI PET/CT was higher than that in the 2-day protocol. The average radiation dose in one-stop FDG-FAPI PET/CT was significantly lower than that in the 2-day protocol (P<0.001).

CONCLUSION

One-stop FDG-FAPI PET/CT at 34 min could provide sufficient information to meet clinical diagnosis and showed better lesion detectability than that in the 2-day protocol.

摘要

目的

验证在注射[镓]Ga-成纤维细胞活化蛋白抑制剂-04([镓]Ga-FAPI-04)后34分钟进行一站式2-[氟]氟-2-脱氧-D-葡萄糖([氟]FDG)和[镓]Ga-FAPI-04双低活性示踪剂正电子发射断层扫描/计算机断层扫描(PET/CT)的可行性,并探讨其附加价值。

方法

本回顾性研究纳入了30例接受双示踪剂成像的疑似恶性肿瘤患者。在额外注射[镓]Ga-FAPI-04后34 - 39分钟和50 - 60分钟重建图像(在一站式FDG-FAPI PET/CT中,分别命名为PET₁、PET₂和PET₃;在两日方案中,分别命名为PET₄、PET₅和PET₆)。分别评估PET₁、PET₂和PET₃中病变的肿瘤与正常组织比值(TNR)以及PET₄和PET₅中病变的TNR。为了评估一站式FDG-FAPI PET/CT相对于两日方案的潜在附加价值,将PET₁、PET₂和PET₃的TNR与PET₄进行比较。通过卡方检验评估两种成像方案的病变可检测性。

结果

在一站式FDG-FAPI PET/CT中,比较FAPI加权PET(PET₁和PET₂)和单示踪剂成像(PET₃),FAPI加权PET的TNR高于PET₃。PET₁和PET₂在病变可检测性和TNR方面表现相似(所有P>0.05)。在两日方案中,PET₄和PET₅中所有病变的TNR无统计学显著差异。将一站式FDG-FAPI PET/CT与两日方案进行比较,PET₁的TNR显著高于PET₄,但低于PET₂和PET₅。一站式FDG-FAPI PET/CT中的病变可检测性高于两日方案。一站式FDG-FAPI PET/CT的平均辐射剂量显著低于两日方案(P<0.001)。

结论

34分钟的一站式FDG-FAPI PET/CT能够提供足够的信息以满足临床诊断,并且与两日方案相比具有更好的病变可检测性。

相似文献

1
Exploration the feasibility and additional value of [F]FDG/[Ga]Ga-FAPI-04 dual-low-activity-tracer one-stop total-body PET imaging at 34 min post-injection of [Ga]Ga-FAPI-04.在注射[镓]Ga-FAPI-04后34分钟,探索[氟]FDG/[镓]Ga-FAPI-04双低活度示踪剂一站式全身PET成像的可行性和附加价值。
Eur J Nucl Med Mol Imaging. 2025 Jan;52(2):638-647. doi: 10.1007/s00259-024-06924-2. Epub 2024 Sep 25.
2
One-stop [F]FDG and [Ga]Ga-DOTA-FAPI-04 total-body PET/CT examination with dual-low activity: a feasibility study.一站式 [F]FDG 和 [Ga]Ga-DOTA-FAPI-04 全身 PET/CT 检查采用双低活度:一项可行性研究。
Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2271-2281. doi: 10.1007/s00259-023-06207-2. Epub 2023 Mar 27.
3
One-Stop 68 Ga-FAPI/ 18 F-FDG Total-Body PET/CT Scan : More Theranostics Information Available.一站式68 Ga-FAPI/ 18 F-FDG全身PET/CT扫描:可提供更多治疗诊断信息。
Clin Nucl Med. 2025 May 1;50(5):e253-e261. doi: 10.1097/RLU.0000000000005673. Epub 2025 Feb 25.
4
Dual-tracer PET/CT protocol with [F]FDG and [Ga]Ga-FAPI-46 outperforms single-tracer PET/CT with [F]FDG in different cancer types, resulting in larger functional and gross tumor volume.双示踪剂 PET/CT 方案([F]FDG 和 [Ga]Ga-FAPI-46)优于单示踪剂 PET/CT([F]FDG),在不同类型的癌症中,可获得更大的功能和大体肿瘤体积。
Strahlenther Onkol. 2024 Jan;200(1):28-38. doi: 10.1007/s00066-023-02117-2. Epub 2023 Aug 16.
5
The earliest optimal timing for total-body Ga-fibroblast activation protein inhibitor-04 PET scans: an evidence-based single-centre study.全身镓纤维母细胞激活蛋白抑制剂-04正电子发射断层扫描的最早最佳时机:一项基于证据的单中心研究。
Eur Radiol. 2024 Jul;34(7):4550-4560. doi: 10.1007/s00330-023-10264-4. Epub 2023 Dec 18.
6
Same-Day Positron Emission Tomography/Computed Tomography with Ga-Radiolabeled Fibroblast Activation Protein Inhibitors and F-Fluorodeoxyglucose Imaging for Gastrointestinal Cancers.同日进行的正电子发射断层扫描/计算机断层扫描,使用镓标记的成纤维细胞活化蛋白抑制剂和氟代脱氧葡萄糖成像用于胃肠道癌
Cancer Biother Radiopharm. 2025 Mar;40(2):130-138. doi: 10.1089/cbr.2024.0182. Epub 2024 Oct 28.
7
Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with F-FDG PET/CT.镓-DOTA-FAPI-04 PET/MR 在胃癌评估中的应用:与 F-FDG PET/CT 的比较。
J Nucl Med. 2022 Jan;63(1):81-88. doi: 10.2967/jnumed.120.258467. Epub 2021 Apr 16.
8
Head-to-head comparison of F-FDG and Ga-FAPI PET/CT in common gynecological malignancies.¹⁸F-FDG与⁶⁸Ga-FAPI PET/CT在常见妇科恶性肿瘤中的头对头比较。
Cancer Imaging. 2025 Feb 28;25(1):21. doi: 10.1186/s40644-025-00843-7.
9
Clinical Explorations of [Ga] Ga-FAPI-04 and [F] FDG Dual-Tracer Total-body PET/CT and PET/MR Imaging.[Ga] Ga-FAPI-04 与 [F] FDG 双示踪剂全身 PET/CT 和 PET/MR 成像的临床探索。
Semin Nucl Med. 2024 Nov;54(6):904-913. doi: 10.1053/j.semnuclmed.2024.09.009. Epub 2024 Nov 2.
10
Dual-Tracer PET/CT Protocol with [F]-FDG and [Ga]Ga-FAPI-46 for Cancer Imaging: A Proof of Concept.基于[F]-FDG 和 [Ga]Ga-FAPI-46 的双重示踪剂 PET/CT 协议在癌症成像中的应用:概念验证。
J Nucl Med. 2022 Nov;63(11):1683-1686. doi: 10.2967/jnumed.122.263835. Epub 2022 Apr 14.

引用本文的文献

1
Recent advances in theranostics and oncology PET: emerging radionuclides and targets.治疗诊断学与肿瘤学PET的最新进展:新兴放射性核素与靶点
Ann Nucl Med. 2025 Sep;39(9):909-921. doi: 10.1007/s12149-025-02090-z. Epub 2025 Jul 27.
2
Beyond skin deep: total-body positron emission tomography to illuminate systemic inflammation in psoriatic arthritis.深入肌肤之下:全身正电子发射断层扫描揭示银屑病关节炎中的全身炎症
Curr Opin Immunol. 2025 Jun 19;95:102587. doi: 10.1016/j.coi.2025.102587.

本文引用的文献

1
The earliest optimal timing for total-body Ga-fibroblast activation protein inhibitor-04 PET scans: an evidence-based single-centre study.全身镓纤维母细胞激活蛋白抑制剂-04正电子发射断层扫描的最早最佳时机:一项基于证据的单中心研究。
Eur Radiol. 2024 Jul;34(7):4550-4560. doi: 10.1007/s00330-023-10264-4. Epub 2023 Dec 18.
2
One-stop [F]FDG and [Ga]Ga-DOTA-FAPI-04 total-body PET/CT examination with dual-low activity: a feasibility study.一站式 [F]FDG 和 [Ga]Ga-DOTA-FAPI-04 全身 PET/CT 检查采用双低活度:一项可行性研究。
Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2271-2281. doi: 10.1007/s00259-023-06207-2. Epub 2023 Mar 27.
3
FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease.
FAPI PET:成纤维细胞激活蛋白抑制剂在肿瘤和非肿瘤疾病中的应用。
Radiology. 2023 Feb;306(2):e220749. doi: 10.1148/radiol.220749. Epub 2023 Jan 3.
4
Non-oncologic incidental uptake on FAPI PET/CT imaging.FAPI PET/CT 成像上的非肿瘤偶然摄取。
Br J Radiol. 2023 Feb;96(1142):20220463. doi: 10.1259/bjr.20220463. Epub 2022 Jul 13.
5
Expert consensus on oncological [F]FDG total-body PET/CT imaging (version 1).肿瘤学 [F]FDG 全身 PET/CT 成像专家共识(第 1 版)。
Eur Radiol. 2023 Jan;33(1):615-626. doi: 10.1007/s00330-022-08960-8. Epub 2022 Jun 25.
6
Fibroblast heterogeneity in solid tumors: From single cell analysis to whole-body imaging.实体瘤中成纤维细胞的异质性:从单细胞分析到全身成像。
Semin Cancer Biol. 2022 Nov;86(Pt 3):262-272. doi: 10.1016/j.semcancer.2022.04.008. Epub 2022 Apr 27.
7
Dual-Tracer PET/CT Protocol with [F]-FDG and [Ga]Ga-FAPI-46 for Cancer Imaging: A Proof of Concept.基于[F]-FDG 和 [Ga]Ga-FAPI-46 的双重示踪剂 PET/CT 协议在癌症成像中的应用:概念验证。
J Nucl Med. 2022 Nov;63(11):1683-1686. doi: 10.2967/jnumed.122.263835. Epub 2022 Apr 14.
8
Imaging Cancer-Associated Fibroblasts (CAFs) with FAPi PET.使用FAPi PET对癌症相关成纤维细胞(CAF)进行成像。
Biomedicines. 2022 Feb 23;10(3):523. doi: 10.3390/biomedicines10030523.
9
Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.基于成纤维细胞激活蛋白抑制剂的放射性药物的临床总结:癌症及其他。
Eur J Nucl Med Mol Imaging. 2022 Jul;49(8):2844-2868. doi: 10.1007/s00259-022-05706-y. Epub 2022 Jan 31.
10
Tumor Imaging With 68Ga-DOTA-FAPI-04 PET/CT: Comparison With 18F-FDG PET/CT in 22 Different Cancer Types.68Ga-DOTA-FAPI-04 PET/CT 肿瘤成像:与 18F-FDG PET/CT 在 22 种不同癌症类型中的比较。
Clin Nucl Med. 2022 Apr 1;47(4):e333-e339. doi: 10.1097/RLU.0000000000004073.